Japanese firm Hisamitsu Pharmaceutical Co. Inc. has offered to buy Noven Pharmaceuticals Inc. for about $428 million in a move that would combine transdermal drug delivery technologies of both firms and expand Hisamitsu's presence in the U.S. (BioWorld Today)

It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc. hardly could have asked for better terms in its ex-U.S. licensing deal for multiple sclerosis drug Fampridine-SR. (BioWorld Today)